Literature DB >> 34101067

Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression.

Ryo Saito1, Hiromichi Kawaida1, Naohiro Hosomura1, Hidetake Amemiya1, Jun Itakura1, Atsushi Yamamoto1, Koichi Takiguchi1, Suguru Maruyama1, Katsutoshi Shoda1, Shinji Furuya1, Hidenori Akaike1, Yoshihiko Kawaguchi1, Makoto Sudo1, Shingo Inoue1, Hiroshi Kono1, Daisuke Ichikawa2.   

Abstract

BACKGROUND: Pancreatectomy is a highly invasive procedure with extensive intraoperative blood loss (IBL) and high risk of postoperative pancreatic fistula (POPF). We conducted an experimental and retrospective clinical study to determine whether the malignant behaviors of pancreatic cancer cells were enhanced by exposure to blood components in vitro and to evaluate the oncological significance of high IBL and POPF in pancreatic cancer.
METHODS: This study included 107 patients undergoing radical pancreatectomy in the University of Yamanashi Hospital between 2011 and 2017, classified into high (n = 29) and low (n = 78) IBL groups. In vitro experiments included functional analyses of Panc-1 pancreatic cancer and normal mesothelial cells exposed to patient blood components, and clinical data were used to assess the contribution of IBL and POPF to patient outcomes.
RESULTS: The migration (p = 0.007), invasion (p < 0.001), and proliferation (p < 0.01) of Panc-1 cells were enhanced with platelet coculture. The ability of Panc-1 cells to adhere mesothelial cells was enhanced by plasma coincubation, especially in the presence of inflammation (p < 0.001). High IBL was associated with worse overall survival (p = 0.007) and increased locoregional recurrence (p = 0.003) in patients. POPF enhanced the negative prognostic significance of high IBL (p < 0.001 for overall survival, p = 0.001 for locoregional recurrence), indicating the oncological negative effects of high IBL and POPF.
CONCLUSIONS: Blood components, especially platelets, and inflammation enhance the malignant behaviors of pancreatic cancer cells, potentially contributing to poor prognosis for pancreatic cancer patients.

Entities:  

Year:  2021        PMID: 34101067     DOI: 10.1245/s10434-021-10250-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy.

Authors:  Wataru Kimura; Hiroaki Miyata; Mitsukazu Gotoh; Ichiro Hirai; Akira Kenjo; Yuko Kitagawa; Mitsuo Shimada; Hideo Baba; Naohiro Tomita; Tohru Nakagoe; Kenichi Sugihara; Masaki Mori
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

2.  Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Chandrajit P Raut; Jennifer F Tseng; Charlotte C Sun; Huamin Wang; Robert A Wolff; Christopher H Crane; Rosa Hwang; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

3.  Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer.

Authors:  Kota Arima; Daisuke Hashimoto; Hirohisa Okabe; Risa Inoue; Takayoshi Kaida; Takaaki Higashi; Katsunobu Taki; Hidetoshi Nitta; Hiromitsu Hayashi; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Surg Today       Date:  2015-08-25       Impact factor: 2.549

4.  Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.

Authors:  W Hartwig; A Gluth; U Hinz; D Koliogiannis; O Strobel; T Hackert; J Werner; M W Büchler
Journal:  Br J Surg       Date:  2016-09-30       Impact factor: 6.939

5.  Postoperative pancreatic fistula: We need to redefine grades B and C.

Authors:  Thilo Hackert; Ulf Hinz; Thomas Pausch; Irina Fesenbeck; Oliver Strobel; Lutz Schneider; Stefan Fritz; Markus W Büchler
Journal:  Surgery       Date:  2015-10-23       Impact factor: 3.982

6.  Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-institutional Dataset.

Authors:  Yuki Ito; Mitsuro Kanda; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

7.  Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer.

Authors:  Takao Kamei; Joji Kitayama; Hiroharu Yamashita; Hirokazu Nagawa
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

8.  Postoperative Systemic Inflammatory Response, Complication Severity, and Survival Following Surgery for Colorectal Cancer.

Authors:  Stephen T McSorley; David G Watt; Paul G Horgan; Donald C McMillan
Journal:  Ann Surg Oncol       Date:  2016-03-25       Impact factor: 5.344

Review 9.  Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer.

Authors:  Koki Nakanishi; Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2019-06-14       Impact factor: 5.742

10.  Platelets enhance malignant behaviours of gastric cancer cells via direct contacts.

Authors:  Ryo Saito; Katsutoshi Shoda; Suguru Maruyama; Atsushi Yamamoto; Koichi Takiguchi; Shinji Furuya; Naohiro Hosomura; Hidenori Akaike; Yoshihiko Kawaguchi; Hidetake Amemiya; Hiromichi Kawaida; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Katsue Suzuki-Inoue; Daisuke Ichikawa
Journal:  Br J Cancer       Date:  2020-10-28       Impact factor: 7.640

View more
  1 in total

Review 1.  Challenges and Opportunities Associated With Platelets in Pancreatic Cancer.

Authors:  Zhou Chen; Xiaodong Wei; Shi Dong; Fangfang Han; Ru He; Wence Zhou
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.